Key result
Immunization with the synthetic peptide F164 induced protective neutralizing antibodies in mice, rendering 87% to 100% of them refractory to a lethal challenge of Mengo virus.
Why the study?
Does synthetic peptide F164 induce protective neutralizing antibodies against Mengo virus in mice and guinea-pigs?
Does synthetic peptide F164 induce protective neutralizing antibodies against Mengo virus in mice and guinea-pigs?
A synthetic peptide from the Mengo virus capsid protein VP1 can induce protective neutralizing antibodies in mice, providing a useful model for studying viral immunogenicity.
Preclinical support for F164 peptide vaccines; leaves open translation to human Mengo virus protection.
A peptide from the carboxyl-terminal region of the Mengo virus capsid protein VP1, representing residues 259 to 277, can induce serum neutralizing (SN) antibodies in both the mouse and guinea-pig. This peptide, termed F164, also induces high levels of protective neutralizing antibodies in mice subsequent to immunization; 87 to 100% of mice are refractory to the effects of an intraperitoneal challenge of 100 LD50 of Mengo virus. The mouse model discussed herein will prove useful for studying the immune response to Mengo virus and evaluating the immunogenicity of individual viral components.
No takes yet. Share an insight, caveat, or question.
Muir et al. (1991) studied Mengo virus infection. Synthetic peptide F164 was evaluated on Protection against intraperitoneal challenge of 100 LD50 of Mengo virus. Immunization with the synthetic peptide F164 induced protective neutralizing antibodies in mice, rendering 87% to 100% of them refractory to a lethal challenge of Mengo virus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: